LifeNet Health today announced the launch of AngioGraft® Aortoiliac Artery, the first aortoiliac allograft that provides surgeons with pressurized sizing in addition to traditional flaccid measurements. Offering both measurements allows surgeons to select the graft that best fits their patient’s anatomy, saving valuable operating time by avoiding intraoperative modifications. AngioGraft Aortoiliac Artery also is the first allograft of its kind …

Encompass Health Corp. announced it has entered into a definitive agreement to acquire privately owned Camellia Healthcare and affiliated entities. Camellia Healthcare operates a portfolio of home health, hospice and private duty locations in Mississippi, Alabama, Louisiana and Tennessee and generated revenues of approximately $78 million in 2017. The transaction is expected to close in the second quarter of 2018, …

Abbott and Surmodics announced that the companies have entered into an agreement whereby Abbott will have exclusive worldwide commercialization rights for Surmodics’ SurVeil® drug-coated balloon to treat the superficial femoral artery, which is currently being evaluated in a U.S. pivotal clinical trial. Separately, Abbott also received options to negotiate agreements for Surmodics’ below-the-knee and arteriovenous (AV) fistula drug-coated balloon products, …

VitalConnect®, Inc. announced the launch of the Vista Solution™ platform. The Vista Solution platform enables wireless, real-time, continuous patient monitoring, and delivers a seamless feed of patient data that supports timely caregiver analysis in the hospital or at home. The new platform integrates the company’s existing VitalPatch® wearable biosensor, which is the only FDA cleared Class II device that continuously …

Clarify Medical announced that the United States Patent and Trademark Office has issued US patent 9,901,747, entitled “Phototherapy Light Engine.” The patent covers a precision, targeted phototherapy device using UVB LEDs, reflectors, window filter and thermal management system to optimize therapeutic power and uniformity of narrowband UVB light treatment. The Clarify System’s patented light engine has significant advantages compared to …

ARMS Medical announced they have entered into an exclusive distributor agreement for DermaPure® dermal allograft. The multi-year agreement gives ARMS Medical exclusive rights to distribute the Tissue Regenix biologic to hospitals and surgeons throughout the United States for use in urology and gynecology procedures. David Pennington, vice president of sales for Tissue Regenix BioSurgery, stated, “We chose ARMS Medical as …

Collagen Matrix announced its first entrance into the India market with two product lines, OssiMend® bone graft matrices from its Spine Business Unit and DuraMatrix® membranes from its Dural Repair Business Unit. OssiMend® bone graft matrices are designed to provide a scaffold for a patient to grow new bone and are typically used in spinal fusion surgeries. DuraMatrix® dural repair …

Terumo BCT announced that it will be the exclusive distributor for Stafa Cellular Therapy (StafaCT), a U.S.-based software developer. StafaCT software supports healthcare facilities and cell labs as they manage each phase of the cellular therapy process including patient referral, cell collection and processing, transplant and follow-up. Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular …

Varian announced it has acquired privately-held Montreal-based Evinance Innovation, Inc., a clinical decision support (CDS) software company. This acquisition expands the capabilities of Varian’s 360 Oncology™ care management platform by tightly integrating clinical workflow, decision support, and adherence tracking based on leading cancer care guidelines. The Evinance Decision Support™ platform is designed to improve quality of care by providing clinicians …

Access Vascular announced that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its lead product, the HydroPICC™, a peripherally inserted central catheter, intended for long-term use. In pre-clinical testing, the HydroPICC demonstrated a 30x reduction in platelet count when compared with current market-leading PICC.1 “The FDA clearance of the HydroPICC catheter is an …